[High-dose immunoglobulin therapy of aplastic syndrome].
Idiopathic pure red-cell aplasia was successfully treated by high-dose intravenous immunoglobulin infusions (HDivIg) in 2 patients; 1 of these patients was refractory to other immunosuppressive drugs. We have observed responses to this therapy also in 3 of 5 patients--without pretreatment--with severe aplastic anemia. HDivIg treatment had no significant side effects; patients with aplastic syndromes could be treated as outpatients. Patients responding to HDivIg demonstrated different response patterns to ciclosporin A. Sequential treatment of aplastic syndromes with high-dose prednisone, HDivIg and ciclosporin A was effective in 6 of 7 patients. The results in this pilot study are comparable to those with other immunosuppressive strategies in patients with severe aplastic anemia who lack a bone marrow donor. Optimal dosage, sequence, and duration of this treatment modality remain to be defined.
Bodenstein
H
H
Klinikum Minden, Abteilung für Hämatologie und Onkologie, BRD.
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D016572:Cyclosporine; D011241:Prednisone
Hochdosis-Immunglobulin-Therapie aplastischer Syndrome.